Market Trends of Global Single Cell Analysis Industry
The Research Applications Segment is Expected to Grow at a Good Rate Over the Forecast Period
The research applications segment is expected to hold the maximum share, owing to the high prevalence of cancer, the increasing need for stem cell research, the initiatives for early detection of chronic diseases, and increasing awareness regarding commercially available cancer diagnostics and precision medicine. In the research segment, cancer and immunology are of growing interest among the scientific communities. In January 2022, Amgen entered into a partnership with Generate Biomedicines to discover and create protein therapeutics for five targets across several therapeutic areas and multiple modalities with an early investment of USD 1.9 billion-plus. In December 2021, Canopy Biosciences, a Bruker Company, launched assay kits for ChipCytometry. The Canopy assay kits will be used to quantitatively image dozens of targeted protein biomarkers simultaneously on a single tissue section at a single-cell spatial resolution which will streamline the user experience with ChipCytometry for a shorter pathway to meaningful biological advances. As per clinicaltrials.gov, as of March 2021, there were nearly 23,358 active, ongoing clinical trials in the area of oncology. This specifies the high rate of cancer research being conducted globally, and as the cellular, metabolic and genetic study and evaluation of tumor cells play a vital role in the understanding of various cancers, which in turn leads to the development of effective diagnostics, therapeutics, and treatment options for cancer, the use of single-cell analysis in research application is predicted to witness significant growth.
Furthermore, immunological studies aid in the early detection of therapeutic complications, including many cancer and hematology-based indications, thereby increasing the efficiency of the treatment. According to article in Journal of Immunology Research, 2020, single-cell RNA sequencing and analysis help in studying the immune response to various infections, which can lead to the development of effective vaccines against causal organisms. Furthermore, invasion of the metabolic activities of single cells is increasing the adoption of its analytical tools, thus propelling the growth of the research segment.
The North American Region Holds the Largest Market Share of the Single Cell Analysis Market, and it is Anticipated to Follow Trend the Same Over the Forecast Period
The large share of the North American single-cell analysis market is attributed to factors such as increasing collaborations among prominent players, technological advancements and growing biotechnology and pharmaceutical industries. In recent years, several government initiatives have been launched that are supplementing the growth of the single-cell analysis market in the region. For instance, in March 2022, Biognosys launched an expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with deep biological insights across the entire R&D pipeline, from early-stage discovery to clinical settings. Similarly, in January 2022, Amgen entered into a partnership with Generate Biomedicines to discover and create protein therapeutics for five targets across several therapeutic areas and multiple modalities with an early investment of USD 1.9 billion-plus.
Additionally, the high incidence of chronic diseases such s cancers in the region is driving the market growth. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the United States in 2020, with nearly 612,390 deaths. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the United States.
Also, the existence of major players in the region and new product launches is expected to boost the single-cell analysis market. For instance, in March 2021The United States Food and Drug Administration approved Abecma (idecabtagene vicleucel), to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines of therapy. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Thus, owing to the above-mentioned factors, the single-cell analysis market is expected to witness significant growth over the forecast period in North America.
